Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

Francesca Palandri, Massimo Breccia, Massimiliano Bonifacio, Nicola Polverelli, Elena M. Elli, Giulia Benevolo, Mario Tiribelli, Elisabetta Abruzzese, Alessandra Iurlo, Florian H. Heidel, Micaela Bergamaschi, Alessia Tieghi, Monica Crugnola, Francesco Cavazzini, Gianni Binotto, Alessandro Isidori, Nicola Sgherza, Costanza Bosi, Bruno Martino, Roberto LatagliataGiuseppe Auteri, Luigi Scaffidi, Davide Griguolo, Malgorzata Trawinska, Daniele Cattaneo, Lucia Catani, Mauro Krampera, Roberto M. Lemoli, Antonio Cuneo, Gianpietro Semenzato, Robin Foà, Francesco Di Raimondo, Daniela Bartoletti, Michele Cavo, Giuseppe A. Palumbo, Nicola Vianelli

Research output: Contribution to journalArticle

Abstract

Background: After discontinuing ruxolitinib, the outcome of patients with myelofibrosis reportedly has been poor. The authors investigated whether disease characteristics before the receipt of ruxolitinib may predict drug discontinuation in patients with myelofibrosis and whether reasons for drug discontinuation, disease phase at discontinuation, and salvage therapies may influence the outcome. Methods: A centralized electronic clinical database was created in 20 European hematology centers, including clinical and laboratory data for 524 patients who received ruxolitinib for myelofibrosis. Results: At 3 years, 40.8% of patients had stopped ruxolitinib. Baseline predictors of drug discontinuation were: intermediate-2–risk/high-risk category (Dynamic International Prognostic Score System), a platelet count <100 ×109 per liter, transfusion dependency, and unfavorable karyotype. At last contact, 268 patients (51.1%) had discontinued therapy, and the median drug exposure was 17.5 months. Fifty patients (18.7%) died while taking ruxolitinib. The reasons for discontinuation in the remaining 218 patients were the lack (22.9%) or loss (11.9%) of a spleen response, ruxolitinib-related adverse events (27.5%), progression to blast phase (23.4%), ruxolitinib-unrelated adverse events (9.2%), and allogeneic transplantation during response (5.1%). The median survival after ruxolitinib was 13.2 months and was significantly better in the 167 patients who discontinued ruxolitinib in chronic phase (27.5 vs 3.9 months for those who discontinued in blast phase; P <.001). No survival differences were observed among patients who discontinued ruxolitinib in chronic phase because of lack of response, loss of response, or ruxolitinib-related adverse events. The use of investigational agents and/or ruxolitinib rechallenge were associated with improved outcome. Conclusions: The survival of patients with myelofibrosis after discontinuation of ruxolitinib is poor, particularly for those who discontinue in blast phase. Salvage therapies can improve outcome, emphasizing the need for novel therapies.

Original languageEnglish
JournalCancer
DOIs
Publication statusAccepted/In press - Jan 1 2019

Keywords

  • investigational agents
  • myelofibrosis
  • outcome
  • ruxolitinib
  • treatment failure

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Palandri, F., Breccia, M., Bonifacio, M., Polverelli, N., Elli, E. M., Benevolo, G., ... Vianelli, N. (Accepted/In press). Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer. https://doi.org/10.1002/cncr.32664

Life after ruxolitinib : Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. / Palandri, Francesca; Breccia, Massimo; Bonifacio, Massimiliano; Polverelli, Nicola; Elli, Elena M.; Benevolo, Giulia; Tiribelli, Mario; Abruzzese, Elisabetta; Iurlo, Alessandra; Heidel, Florian H.; Bergamaschi, Micaela; Tieghi, Alessia; Crugnola, Monica; Cavazzini, Francesco; Binotto, Gianni; Isidori, Alessandro; Sgherza, Nicola; Bosi, Costanza; Martino, Bruno; Latagliata, Roberto; Auteri, Giuseppe; Scaffidi, Luigi; Griguolo, Davide; Trawinska, Malgorzata; Cattaneo, Daniele; Catani, Lucia; Krampera, Mauro; Lemoli, Roberto M.; Cuneo, Antonio; Semenzato, Gianpietro; Foà, Robin; Di Raimondo, Francesco; Bartoletti, Daniela; Cavo, Michele; Palumbo, Giuseppe A.; Vianelli, Nicola.

In: Cancer, 01.01.2019.

Research output: Contribution to journalArticle

Palandri, F, Breccia, M, Bonifacio, M, Polverelli, N, Elli, EM, Benevolo, G, Tiribelli, M, Abruzzese, E, Iurlo, A, Heidel, FH, Bergamaschi, M, Tieghi, A, Crugnola, M, Cavazzini, F, Binotto, G, Isidori, A, Sgherza, N, Bosi, C, Martino, B, Latagliata, R, Auteri, G, Scaffidi, L, Griguolo, D, Trawinska, M, Cattaneo, D, Catani, L, Krampera, M, Lemoli, RM, Cuneo, A, Semenzato, G, Foà, R, Di Raimondo, F, Bartoletti, D, Cavo, M, Palumbo, GA & Vianelli, N 2019, 'Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis', Cancer. https://doi.org/10.1002/cncr.32664
Palandri, Francesca ; Breccia, Massimo ; Bonifacio, Massimiliano ; Polverelli, Nicola ; Elli, Elena M. ; Benevolo, Giulia ; Tiribelli, Mario ; Abruzzese, Elisabetta ; Iurlo, Alessandra ; Heidel, Florian H. ; Bergamaschi, Micaela ; Tieghi, Alessia ; Crugnola, Monica ; Cavazzini, Francesco ; Binotto, Gianni ; Isidori, Alessandro ; Sgherza, Nicola ; Bosi, Costanza ; Martino, Bruno ; Latagliata, Roberto ; Auteri, Giuseppe ; Scaffidi, Luigi ; Griguolo, Davide ; Trawinska, Malgorzata ; Cattaneo, Daniele ; Catani, Lucia ; Krampera, Mauro ; Lemoli, Roberto M. ; Cuneo, Antonio ; Semenzato, Gianpietro ; Foà, Robin ; Di Raimondo, Francesco ; Bartoletti, Daniela ; Cavo, Michele ; Palumbo, Giuseppe A. ; Vianelli, Nicola. / Life after ruxolitinib : Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. In: Cancer. 2019.
@article{e7d0fa81551d4a3596bbd14be8491810,
title = "Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis",
abstract = "Background: After discontinuing ruxolitinib, the outcome of patients with myelofibrosis reportedly has been poor. The authors investigated whether disease characteristics before the receipt of ruxolitinib may predict drug discontinuation in patients with myelofibrosis and whether reasons for drug discontinuation, disease phase at discontinuation, and salvage therapies may influence the outcome. Methods: A centralized electronic clinical database was created in 20 European hematology centers, including clinical and laboratory data for 524 patients who received ruxolitinib for myelofibrosis. Results: At 3 years, 40.8{\%} of patients had stopped ruxolitinib. Baseline predictors of drug discontinuation were: intermediate-2–risk/high-risk category (Dynamic International Prognostic Score System), a platelet count <100 ×109 per liter, transfusion dependency, and unfavorable karyotype. At last contact, 268 patients (51.1{\%}) had discontinued therapy, and the median drug exposure was 17.5 months. Fifty patients (18.7{\%}) died while taking ruxolitinib. The reasons for discontinuation in the remaining 218 patients were the lack (22.9{\%}) or loss (11.9{\%}) of a spleen response, ruxolitinib-related adverse events (27.5{\%}), progression to blast phase (23.4{\%}), ruxolitinib-unrelated adverse events (9.2{\%}), and allogeneic transplantation during response (5.1{\%}). The median survival after ruxolitinib was 13.2 months and was significantly better in the 167 patients who discontinued ruxolitinib in chronic phase (27.5 vs 3.9 months for those who discontinued in blast phase; P <.001). No survival differences were observed among patients who discontinued ruxolitinib in chronic phase because of lack of response, loss of response, or ruxolitinib-related adverse events. The use of investigational agents and/or ruxolitinib rechallenge were associated with improved outcome. Conclusions: The survival of patients with myelofibrosis after discontinuation of ruxolitinib is poor, particularly for those who discontinue in blast phase. Salvage therapies can improve outcome, emphasizing the need for novel therapies.",
keywords = "investigational agents, myelofibrosis, outcome, ruxolitinib, treatment failure",
author = "Francesca Palandri and Massimo Breccia and Massimiliano Bonifacio and Nicola Polverelli and Elli, {Elena M.} and Giulia Benevolo and Mario Tiribelli and Elisabetta Abruzzese and Alessandra Iurlo and Heidel, {Florian H.} and Micaela Bergamaschi and Alessia Tieghi and Monica Crugnola and Francesco Cavazzini and Gianni Binotto and Alessandro Isidori and Nicola Sgherza and Costanza Bosi and Bruno Martino and Roberto Latagliata and Giuseppe Auteri and Luigi Scaffidi and Davide Griguolo and Malgorzata Trawinska and Daniele Cattaneo and Lucia Catani and Mauro Krampera and Lemoli, {Roberto M.} and Antonio Cuneo and Gianpietro Semenzato and Robin Fo{\`a} and {Di Raimondo}, Francesco and Daniela Bartoletti and Michele Cavo and Palumbo, {Giuseppe A.} and Nicola Vianelli",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/cncr.32664",
language = "English",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Life after ruxolitinib

T2 - Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

AU - Palandri, Francesca

AU - Breccia, Massimo

AU - Bonifacio, Massimiliano

AU - Polverelli, Nicola

AU - Elli, Elena M.

AU - Benevolo, Giulia

AU - Tiribelli, Mario

AU - Abruzzese, Elisabetta

AU - Iurlo, Alessandra

AU - Heidel, Florian H.

AU - Bergamaschi, Micaela

AU - Tieghi, Alessia

AU - Crugnola, Monica

AU - Cavazzini, Francesco

AU - Binotto, Gianni

AU - Isidori, Alessandro

AU - Sgherza, Nicola

AU - Bosi, Costanza

AU - Martino, Bruno

AU - Latagliata, Roberto

AU - Auteri, Giuseppe

AU - Scaffidi, Luigi

AU - Griguolo, Davide

AU - Trawinska, Malgorzata

AU - Cattaneo, Daniele

AU - Catani, Lucia

AU - Krampera, Mauro

AU - Lemoli, Roberto M.

AU - Cuneo, Antonio

AU - Semenzato, Gianpietro

AU - Foà, Robin

AU - Di Raimondo, Francesco

AU - Bartoletti, Daniela

AU - Cavo, Michele

AU - Palumbo, Giuseppe A.

AU - Vianelli, Nicola

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: After discontinuing ruxolitinib, the outcome of patients with myelofibrosis reportedly has been poor. The authors investigated whether disease characteristics before the receipt of ruxolitinib may predict drug discontinuation in patients with myelofibrosis and whether reasons for drug discontinuation, disease phase at discontinuation, and salvage therapies may influence the outcome. Methods: A centralized electronic clinical database was created in 20 European hematology centers, including clinical and laboratory data for 524 patients who received ruxolitinib for myelofibrosis. Results: At 3 years, 40.8% of patients had stopped ruxolitinib. Baseline predictors of drug discontinuation were: intermediate-2–risk/high-risk category (Dynamic International Prognostic Score System), a platelet count <100 ×109 per liter, transfusion dependency, and unfavorable karyotype. At last contact, 268 patients (51.1%) had discontinued therapy, and the median drug exposure was 17.5 months. Fifty patients (18.7%) died while taking ruxolitinib. The reasons for discontinuation in the remaining 218 patients were the lack (22.9%) or loss (11.9%) of a spleen response, ruxolitinib-related adverse events (27.5%), progression to blast phase (23.4%), ruxolitinib-unrelated adverse events (9.2%), and allogeneic transplantation during response (5.1%). The median survival after ruxolitinib was 13.2 months and was significantly better in the 167 patients who discontinued ruxolitinib in chronic phase (27.5 vs 3.9 months for those who discontinued in blast phase; P <.001). No survival differences were observed among patients who discontinued ruxolitinib in chronic phase because of lack of response, loss of response, or ruxolitinib-related adverse events. The use of investigational agents and/or ruxolitinib rechallenge were associated with improved outcome. Conclusions: The survival of patients with myelofibrosis after discontinuation of ruxolitinib is poor, particularly for those who discontinue in blast phase. Salvage therapies can improve outcome, emphasizing the need for novel therapies.

AB - Background: After discontinuing ruxolitinib, the outcome of patients with myelofibrosis reportedly has been poor. The authors investigated whether disease characteristics before the receipt of ruxolitinib may predict drug discontinuation in patients with myelofibrosis and whether reasons for drug discontinuation, disease phase at discontinuation, and salvage therapies may influence the outcome. Methods: A centralized electronic clinical database was created in 20 European hematology centers, including clinical and laboratory data for 524 patients who received ruxolitinib for myelofibrosis. Results: At 3 years, 40.8% of patients had stopped ruxolitinib. Baseline predictors of drug discontinuation were: intermediate-2–risk/high-risk category (Dynamic International Prognostic Score System), a platelet count <100 ×109 per liter, transfusion dependency, and unfavorable karyotype. At last contact, 268 patients (51.1%) had discontinued therapy, and the median drug exposure was 17.5 months. Fifty patients (18.7%) died while taking ruxolitinib. The reasons for discontinuation in the remaining 218 patients were the lack (22.9%) or loss (11.9%) of a spleen response, ruxolitinib-related adverse events (27.5%), progression to blast phase (23.4%), ruxolitinib-unrelated adverse events (9.2%), and allogeneic transplantation during response (5.1%). The median survival after ruxolitinib was 13.2 months and was significantly better in the 167 patients who discontinued ruxolitinib in chronic phase (27.5 vs 3.9 months for those who discontinued in blast phase; P <.001). No survival differences were observed among patients who discontinued ruxolitinib in chronic phase because of lack of response, loss of response, or ruxolitinib-related adverse events. The use of investigational agents and/or ruxolitinib rechallenge were associated with improved outcome. Conclusions: The survival of patients with myelofibrosis after discontinuation of ruxolitinib is poor, particularly for those who discontinue in blast phase. Salvage therapies can improve outcome, emphasizing the need for novel therapies.

KW - investigational agents

KW - myelofibrosis

KW - outcome

KW - ruxolitinib

KW - treatment failure

UR - http://www.scopus.com/inward/record.url?scp=85076740385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076740385&partnerID=8YFLogxK

U2 - 10.1002/cncr.32664

DO - 10.1002/cncr.32664

M3 - Article

AN - SCOPUS:85076740385

JO - Cancer

JF - Cancer

SN - 0008-543X

ER -